In the months before it secured a federal financing deal worth $765 million to help produce COVID-19 drugs, camera giant-turned-pharmaceutical company Eastman Kodak jump-started its dormant lobbying operation, spending unprecedented sums to influence D.C. policymakers.
Kodak’s in-house lobbying team had officially dissolved in early 2019, according to disclosure filings submitted to federal regulators. But on April 1 of this year, the company started it back up, and proceeded to plow $870,000 into its D.C. influence machine. That sum, which went towards influencing both Congress and the administration, was more than twice as much as Kodak had ever spent on lobbying in any quarterly reporting period.
The effort appears to have paid off handsomely.